Table 2.

Tumor Growth Delay and Tumor Volume Growth Inhibition in Adenovirus-Infected MDA-MB-231 Tumors^a

A. Tumor Growth Delay
Tumor growth delay data	Days to 2×	2× tumor growth delay (days)	Days to 5×	5× tumor growth delay (days)
Control	7.08 ± 0.88	N/A	22.67 ± 2.46	N/A
Adeno-hTERT-E1A	17.58 ± 2.22b,c	10.5 ± 3.10	46.00 ± 2.60b,c	23.33 ± 5.06
ONYX-015	9.58 ± 1.30	2.5 ± 2.18	33.75 ± 2.36d	11.08 ± 4.82

B. Tumor Growth Inhibition
Tumor growth inhibition data	Virus	Tumor growth inhibition (%)
Treatment period 1 (days 0 to 18)	Adeno-hTERT-E1A	44.9 ± 3.2b,c
	ONYX-015	25.8 ± 5.6e
Treatment period 2 (days 0 to 46)	Adeno-hTERT-E1A	63.5 ± 4.6b,f
	ONYX-015	42.1 ± 10.8g

Abbreviation: N/A, Not applicable.

All p values determined by one-way ANOVA with Bonferroni multiple comparison.

^aTumor-bearing mice were treated with Adeno-hTERT-E1A or ONYX-015 by intratumoral injection as described in Fig. 7. Tumor growth delay (A) and tumor growth inhibition (B) were calculated in comparison with control tumors as described in Materials and Methods. Inhibition data were normalized by setting the last measurement of the control group (days 18 and 46 for treatment periods 1 and 2, respectively) to 100%. Tumor growth delay and growth inhibition data are presented as percent means ± SE based on n = 12 tumors per group.

^bp < 0.001 (control vs. Adeno-hTERT-E1A).

^cp < 0.01 (Adeno-hTERT-E1A vs. ONYX-015).

^dp < 0.05 (control vs. ONYX-015).

^ep < 0.001 (control vs. ONYX-015).

^fp < 0.05 (Adeno-hTERT-E1A vs. ONYX-015).

^gp < 0.01 (control vs. ONYX-015).